Pace Of Omicron Variants Hindering Work On Adapted COVID-19 Vaccines
Executive Summary
The European Medicines Agency says regulators are currently discussing the extent to which clinical data will have to be submitted to support the approval of an adapted vaccine against Omicron variants.
You may also be interested in...
Coronavirus Notebook: Australia To Assess Omicron-Adapted Vaccine Riltozinameran, EU Advises On Boosters For Older & Vulnerable People
The EMA has drawn up a list of groups of critical medicines for use in health emergencies, while the European Parliament’s special COVID-19 committee is to discuss vaccination campaigns and challenges with the chiefs of the ECDC and HERA.
EMA Assessing Variant-Adapted Spikevax, Probes Heart Inflammation With Nuvaxovid
A rolling review of an adapted version of Moderna’s COVID-19 vaccine Spikevax aimed at variants of SARS-CoV-2 has begun at the European Medicines Agency. The EMA has also given an update on its latest vaccine safety reviews, including reports of heavy menstrual bleeding with Spikevax and Comirnaty.
Coronavirus Notebook: Adapted Comirnaty Vaccine Under EU Review, Sanofi & GSK Laud Next-Gen Booster
Valneva expects its vaccine candidate to be approved this month. Meanwhile, the core functions of the UK’s Vaccine Taskforce are to be transferred to the UK Health Security Agency and the Office for Life Sciences.